Cases & Deals

Share

Cellectis completes $228 million IPO

March 2015

Client(s) Cellectis SA

Jones Day represented Cellectis SA, a French biotechnology company that develops novel cancer treatments, in connection with its $228 million initial public offering in the United States and Nasdaq listing. BofA Merrill Lynch, Jefferies, and Piper Jaffray & Co. acted as lead underwriters for the offering.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.